None\n As drug pipelines continue to expand and shift toward emerging biotech companies, the complexity of developing combination products has never been greater. In this episode of The Top Line, Kelly Hogan speaks with Dr. Bettine Boltres, director of scientific affairs, integrated systems at West Pharmaceutical Services, about how West Synchrony™ S1 prefillable syringe system was designed to address these growing challenges. Dr. Boltres explains how fragmented supplier models creat

None How many of these 7 ADC handling considerations are on your radar?As pipelines for ADCs mature, payloads become more potent, and linker technologies grow more sophisticated, the operational demands surrounding ADC manufacturing are intensifying rapidly. At the same time, development timelines are compressing, and expectations regarding safety, reproducibility, and regulatory compliance continue to rise.What may work for monoclonal antibodies is increasingly insufficient for ADCs. No

VS-214, a Long-Acting Apelin Agonist, Highlighted as a Potential First-in-Class Treatment for Peripheral Artery Disease ENCINITAS, Calif., May 11, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, announced today that its abstract titled, "Discovery of VS-214, a long-acting apelin agonist, as a first-in-class treatment of peripheral artery disease (PAD)", has been selected for oral presentati

Bridge to life highlights study presented as oral late-breaking clinical trial during "The 2026 International Congress of the International Liver Transplantation Society (ILTS)" in Geneva, Switzerland, May 6-9, 2026 DULUTH, Ga. , May 11, 2026 /PRNewswire/ -- A first-of-its-kind global multicenter study has established the first international benchmark framework for pediatric liver transplantation (PLT), providing a long-awaited reference framework for morbidity, complications, graft survival, a

Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled “Inside MEAI: New Insights from the CMND-100 Psychedel

WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development (Beijing) Co., Ltd. (“KunTuo”), a full-service contract research organization (CRO) dedicated to clinical research services in China, today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at providing biotherapeutics devel

4basebio PLC ("4basebio" or the "Company") 4basebio Launches Enzymatic ssDNA Platform Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing faster and more reliable ssDNA manufacturing to aid commercial scale up4basebio team to present at ASGCT Annual Meeting 2026 in Boston, MA CAMBRIDGE, UK – 11 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics,

REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences: Event: H.C. Wainwright 4th Annual BioConnect Investor Conference Date: May 19, 2026 Event: Jefferies Global Healthcare Conference Date: June 2-4, 2026 Management will be participa

The Focus Fund is cultivate(MD)'s fifth vehicle: a 2031-horizon strategy to identify, support, and exit best-in-class early-stage medical device companies. GRAND RAPIDS, Mich., May 11, 2026 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, announced that its Focus Fund has deployed capital across four portfolio companies over the past month. THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER

First Targeted Therapy Approved for NRG1+ Cholangiocarcinoma BIZENGRI Now Approved for Patients Harboring NRG1 Gene Fusions in Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, and Cholangiocarcinoma LEXINGTON, Mass., May 11, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectabl